• 1
    Creutzfeldt W. Chiral switch, a successful way for developing drugs: example of esomeprazole. Z Gastroenterol 2000; 38: 8937.
  • 2
    Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 41126.
  • 3
    Andersson T, Bredberg E, Sunzel M, Antonsson M, Weidolf L. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O). Gastroenterology 2000; 118: A1210 (Abstract).
  • 4
    Äbelö A, Andersson T, Antonsson M, Naudot AK, Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 96672.
  • 5
    Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 2734.
  • 6
    Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundborg P. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Safety 2001; 24: 62535.
  • 7
    Genta R, Magner D, D'Amico D, Levine D. Safety and long-term treatment with a new PPI, esomeprazole in GERD patients. Gastroenterology 2000; 118(Suppl. 2): A16 (Abstract).